Focus: Sequence Bio is a genomic analysis biotechnology company focused on identifying drug targets for oncology. The company operates as a pre-revenue biotech with a highly specialized, research-driven model.
Profile data last refreshed 17h ago · AI intelligence enriched 2w ago
Sequence Bio is a speculative early-stage bet suited only for risk-tolerant scientists seeking deep technical immersion in genomics; career upside depends entirely on company achieving clinical and commercial validation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Sequence Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Sequence Bio's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo